Structure-based identification of pan-arenavirus sites of vulnerability

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1R21AI176379-01A1

Grant search

Key facts

  • Disease

    Lassa Haemorrhagic Fever, Argentine Haemorrhagic Fever
  • Start & end year

    2025.0
    2027.0
  • Known Financial Commitments (USD)

    $536,871
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    CHIEF. Michael Joyce
  • Research Location

    United States of America
  • Lead Research Institution

    HENRY M. JACKSON FDN FOR THE ADV MIL/MED
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

PROJECT SUMMARY Arenaviruses are enveloped RNA viruses with remarkably diverse Old World (OW) and New World (NW) serogroups that cause hemorrhagic fevers, for which there are currently limited treatment options. At present, ribavirin is the only off-label antiviral medication with efficacy against Lassa virus. The global prevalence, pandemic potential, probability for zoonotic transfer, and diversity of arenaviruses therefore justifies a sustained effort to identify and develop therapeutic countermeasures. Accelerated small molecule discovery, in addition to distinguishing novel inhibitors, may also provide essential mechanistic details of viral pathogenesis, revealing the molecular determinants of pan-reactivity of a diverse viral family. The arenavirus surface pre-glycoprotein polyprotein complex (GPC) and RNA polymerase (RNAP) complexes are two critical components of the viral cell entry and replication cycle. Given the overall similarity in molecular architecture and specific localized sequence conservation for each of these molecules across the large arenavirus family, they represent attractive targets for small molecule inhibitor identification. Recent structural information for prototypic OW and NW arenavirus GPCs and RNAPs has provided a foundation for identifying molecules that target structurally conserved, cross-reactive regions of these vital viral proteins. The proposed studies aim to fill a critical void in our understanding of pan- arenavirus sites of vulnerability through machine learning, artificial neural network molecular screening of small molecules against arenavirus GPCs (Aim 1) and RNAPs (Aim 2). Further characterization by in vitro structural, biochemical, and viral neutralization analysis of small molecule candidate inhibitors identified by the in silico screen will allow for inhibitor optimization for future animal challenge studies and combinatorial therapeutic development. By identifying GPC or polymerase-targeting molecules with broad, pan-arenavirus activity, we will define molecular specificities and commonalities of disparate arenavirus GPCs and polymerase complexes to guide immunogen design.